Home/Biosimilar Atlas/Companies/Gennova Biopharmaceuticals

Gennova Biopharmaceuticals

Biosimilar developer, India. 2 development products across 2 molecules: filgrastim, pegfilgrastim.

First approval in the Atlas: Jan 2010, Gennova Biopharmaceuticals (INN only), pegfilgrastim (CDSCO)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved2
EDEproducts registered0
Connections
2molecules2products1 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
FilgrastimGennova filgrastim·····Mar 2010·1/7
PegfilgrastimGennova pegfilgrastim·····Jan 2010·1/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Gennova Biopharmaceuticals, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

CuraTeQ BiologicsTwo shared molecules: filgrastim, pegfilgrastim4 molecules in its portfolioIntas PharmaceuticalsTwo shared molecules: filgrastim, pegfilgrastim12 molecules in its portfolioKashiv BioSciencesTwo shared molecules: filgrastim, pegfilgrastim2 molecules in its portfolioLupinTwo shared molecules: filgrastim, pegfilgrastim6 molecules in its portfolioPfizerTwo shared molecules: filgrastim, pegfilgrastim7 molecules in its portfolioSandozTwo shared molecules: filgrastim, pegfilgrastim10 molecules in its portfolio

Chronology

Compare Gennova Biopharmaceuticals with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.